Tuesday, November 15, 2016
- 9:00AM-11:00AM
-
Abstract Number: 2779
Better Health-Related Quality of Life and Work Capacity in Patients Achieving Inactive Disease and Clinical Response in Patients with Non-Radiographic Axial Spondyloarthritis
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III- 9:00AM-11:00AM
-
Abstract Number: 2237
Biologic DMARD Use Among U.S. Patients in an Online Rheumatoid Arthritis Community
Health Services Research - Poster III- 9:00AM-11:00AM
-
Abstract Number: 2955
Biologic Therapy in Severe Peripheral Ulcerative Keratitis (PUK). Multicenter Study of 27 Patients
Vasculitis - Poster III: Rarer Vasculitides- 9:00AM-11:00AM
-
Abstract Number: 2375
Biologic Therapy Modifies Clinical and Laboratory Features of Macrophage Activation Syndrome Associated with Systemic Juvenile Idiopathic Arthritis
Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster III: Systemic JIA, Autoinflammatory Syndromes, Scleroderma, Vasculitis, Miscellaneous- 9:00AM-11:00AM
-
Abstract Number: 2669
Biological Treatments in Primary SjöGren Syndrome
Sjögren's Syndrome - Poster II: Clinical Science- 9:00AM-11:00AM
-
Abstract Number: 2286
Bioresponsive Glucocorticoid-Loaded Microparticles to Prevent Acute Gout Flares
Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease- 9:00AM-11:00AM
-
Abstract Number: 19L
Biosimilar Infliximab (CT-P13) Is Not Inferior to Originator Infliximab: Results from a 52-Week Randomized Switch Trial in Norway
ACR Late-Breaking Poster Session- 9:00AM-11:00AM
-
Abstract Number: 2436
Birth Outcomes Significantly Worsen after the Development of Systemic Lupus Erythematosus in a Population-Based Registry
Reproductive Issues in Rheumatic Disorders - Poster- 9:00AM-11:00AM
-
Abstract Number: 11L
BMS-986165 Is a Highly Potent and Selective Allosteric Inhibitor of Tyk2, Blocks IL-12, IL-23 and Type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Systemic Lupus Erythematosus and Inflammatory Bowel Disease
ACR Late-Breaking Poster Session- 9:00AM-11:00AM
-
Abstract Number: 2134
Bone Replaces Cartilage in Non-Weight Bearing Regions of Immobilized Knees
Biology and Pathology of Bone and Joint - Poster I- 9:00AM-11:00AM
-
Abstract Number: 2787
Bortezomib Treatment Induces Higher Mortality Rate in Lupus Model Mice with High Disease Activity
Systemic Lupus Erythematosus – Animal Models - Poster II- 9:00AM-11:00AM
-
Abstract Number: 2782
Bortezomib Treatment Prevents Glomerulosclerosis Associated with Lupus Nephritis in a Murine Model through Suppressive Effects on the Immune and Renin-Angiotensin Systems
Systemic Lupus Erythematosus – Animal Models - Poster II- 9:00AM-11:00AM
-
Abstract Number: 2816
Broad Autoantibody Profiling in Ethnically Diverse SLE Cohorts Reveals a Set of Conserved Autoantibodies That Are Correlated to a Type I Interferon Signature
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis- 9:00AM-11:00AM
-
Abstract Number: 2740
Cam Type Femoroacetabular Impingement Morphology Is More Frequent in Patients with Axial Spondyloarthritis